6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Hepatotoxicity	NNP	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
Lung	NNP	lung	lung	lung	N	I-AdverseReaction
Disease	NNP	disease	disease	diseas	N	I-AdverseReaction
Pneumonitis	NNP	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

QT	NNP	qt	qt	qt	N	B-AdverseReaction
Interval	NNP	interval	interval	interv	N	I-AdverseReaction
Prolongation	NNP	prolongation	prolongation	prolong	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Severe	JJ	severe	severe	sever	N	B-Severity
Visual	NNP	visual	visual	visual	N	B-AdverseReaction
Loss	NNP	loss	loss	loss	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
edema	NN	edema	edema	edema	Y	B-AdverseReaction
,	,	,	,	,	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Pfizer	NNP	pfizer	pfizer	pfizer	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
438	CD	438	438	438	N	O
-	:	-	-	-	N	O
1985	CD	1985	1985	1985	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
primarily	RB	primarily	primarily	primarili	N	O
on	IN	on	on	on	N	O
343	CD	343	343	343	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
ALK	NNP	alk	alk	alk	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
250	CD	250	250	250	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
is	VBZ	is	is	is	N	O
supplemented	VBN	supplemented	supplemented	supplement	N	O
with	IN	with	with	with	N	O
information	NN	information	information	inform	N	O
on	IN	on	on	on	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
1326	CD	1326	1326	1326	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
ALK	NNP	alk	alk	alk	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
250	CD	250	250	250	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
1669	CD	1669	1669	1669	N	O
patients	NNS	patients	patient	patient	N	O
across	IN	across	across	across	N	O
all	DT	all	all	all	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
XALKORI	NN	xalkori	xalkori	xalkori	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
are	VBP	are	are	are	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
edema	NN	edema	edema	edema	Y	B-AdverseReaction
,	,	,	,	,	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Previously	RB	previously	previously	previous	N	O
Untreated	VBN	untreated	untreated	untreat	N	O
ALK	NNP	alk	alk	alk	N	O
-	:	-	-	-	N	O
Positive	JJ	positive	positive	posit	N	O
Metastatic	NNP	metastatic	metastatic	metastat	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
-	:	-	-	-	N	O
Study	NN	study	study	studi	N	O
1	CD	1	1	1	N	O

The	DT	the	the	the	N	O
data	NN	data	data	data	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
are	VBP	are	are	are	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
340	CD	340	340	340	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
ALK	NNP	alk	alk	alk	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
not	RB	not	not	not	N	O
received	VBN	received	received	receiv	N	O
previous	JJ	previous	previous	previou	N	O
systemic	JJ	systemic	systemic	system	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
advanced	JJ	advanced	advanced	advanc	N	O
disease	NN	disease	disease	diseas	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
,	,	,	,	,	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
arm	NN	arm	arm	arm	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
171	CD	171	171	171	N	O
)	)	)	)	)	N	O
received	VBD	received	received	receiv	N	O
XALKORI	$	xalkori	xalkori	xalkori	N	O
250	CD	250	250	250	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
twice	JJ	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
until	IN	until	until	until	N	O
documented	JJ	documented	documented	document	N	O
disease	NN	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
,	,	,	,	,	N	O
intolerance	NN	intolerance	intolerance	intoler	N	O
to	TO	to	to	to	N	O
therapy	VB	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
investigator	NN	investigator	investigator	investig	N	O
determined	VBD	determined	determined	determin	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
was	VBD	was	wa	wa	N	O
no	RB	no	no	no	N	O
longer	JJR	longer	longer	longer	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
clinical	JJ	clinical	clinical	clinic	N	O
benefit	NN	benefit	benefit	benefit	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
169	CD	169	169	169	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
arm	NN	arm	arm	arm	N	O
received	VBD	received	received	receiv	N	O
pemetrexed	JJ	pemetrexed	pemetrexed	pemetrex	N	O
500	CD	500	500	500	N	O
mg	NN	mg	mg	mg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
cisplatin	JJ	cisplatin	cisplatin	cisplatin	N	O
75	CD	75	75	75	N	O
mg	NN	mg	mg	mg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
91	CD	91	91	91	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
carboplatin	NN	carboplatin	carboplatin	carboplatin	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
calculated	VBN	calculated	calculated	calcul	N	O
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
an	DT	an	an	an	N	O
area	NN	area	area	area	N	O
under	IN	under	under	under	N	O
the	DT	the	the	the	N	O
concentration	NN	concentration	concentration	concentr	N	O
-	:	-	-	-	N	O
time	NN	time	time	time	N	O
curve	NN	curve	curve	curv	N	O
(	(	(	(	(	N	O
AUC	NNP	auc	auc	auc	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
mg	NNS	mg	mg	mg	N	O
?	.	?	?	?	N	O
min	NN	min	min	min	N	O
mL	NN	ml	ml	ml	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
78	CD	78	78	78	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Chemotherapy	NNP	chemotherapy	chemotherapy	chemotherapi	Y	O
was	VBD	was	wa	wa	N	O
given	VBN	given	given	given	N	O
by	IN	by	by	by	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
infusion	NN	infusion	infusion	infus	Y	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
for	IN	for	for	for	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
cycles	NNS	cycles	cycle	cycl	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
limiting	VBG	limiting	limiting	limit	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
toxicities	NNS	toxicities	toxicity	toxic	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
6	CD	6	6	6	N	O
cycles	NNS	cycles	cycle	cycl	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
remained	VBD	remained	remained	remain	N	O
on	IN	on	on	on	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
no	DT	no	no	no	N	O
additional	JJ	additional	additional	addit	N	O
anticancer	NN	anticancer	anticancer	anticanc	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tumor	NN	tumor	tumor	tumor	N	O
assessments	NNS	assessments	assessment	assess	N	O
continued	VBD	continued	continued	continu	N	O
until	IN	until	until	until	N	O
documented	JJ	documented	documented	document	N	O
disease	NN	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
study	NN	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
10.9	CD	10.9	10.9	10.9	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
4.1	CD	4.1	4.1	4.1	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
5.2	CD	5.2	5.2	5.2	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
after	IN	after	after	after	N	O
cross	NN	cross	cross	cross	N	O
over	IN	over	over	over	N	O
from	IN	from	from	from	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
340	CD	340	340	340	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
53	CD	53	53	53	N	O
years	NNS	years	year	year	N	O
;	:	;	;	;	N	O
16%	CD	16%	16%	16%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
older	JJR	older	older	older	N	O
than	IN	than	than	than	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
62%	CD	62%	62%	62%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
46%	CD	46%	46%	46%	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
58	CD	58	58	58	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
34%	CD	34%	34%	34%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
were	VBD	were	were	were	N	O
dyspnea	NNS	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
(	(	(	(	(	N	O
4.1%	CD	4.1%	4.1%	4.1%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
(	(	(	(	(	N	O
2.9%	CD	2.9%	2.9%	2.9%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
consisting	VBG	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
septic	JJ	septic	septic	septic	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diabetic	JJ	diabetic	diabetic	diabet	Y	B-AdverseReaction
ketoacidosis	NN	ketoacidosis	ketoacidosis	ketoacidosi	Y	I-AdverseReaction
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
required	VBN	required	required	requir	N	O
in	IN	in	in	in	N	O
6.4%	CD	6.4%	6.4%	6.4%	N	O
of	IN	of	of	of	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
nausea	JJ	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
(	(	(	(	(	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
8.2%	CD	8.2%	8.2%	8.2%	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
(	(	(	(	(	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
(	(	(	(	(	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Tables	NNS	tables	table	tabl	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
summarize	JJ	summarize	summarize	summar	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
in	IN	in	in	in	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NNP	incidence	incidence	incid	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
Higher	JJR	higher	higher	higher	N	O
for	IN	for	for	for	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
or	CC	or	or	or	N	O
2%	CD	2%	2%	2%	N	O
Higher	JJR	higher	higher	higher	N	O
for	IN	for	for	for	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
than	IN	than	than	than	N	O
Chemotherapy	NNP	chemotherapy	chemotherapy	chemotherapi	Y	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
171	CD	171	171	171	N	O
)	)	)	)	)	N	O
Chemotherapy	NNP	chemotherapy	chemotherapy	chemotherapi	Y	O
(	(	(	(	(	N	O
Pemetrexed	NNP	pemetrexed	pemetrexed	pemetrex	N	O
Cisplatin	NNP	cisplatin	cisplatin	cisplatin	N	O
or	CC	or	or	or	N	O
Pemetrexed	NNP	pemetrexed	pemetrexed	pemetrex	N	O
Carboplatin	NNP	carboplatin	carboplatin	carboplatin	N	O
)(	NNP	)(	)(	)(	N	O
N	NNP	n	n	n	N	O
169	CD	169	169	169	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Includes	NNS	includes	includes	includ	N	O

cases	NNS	cases	case	case	N	O
reported	VBD	reported	reported	report	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
clustered	JJ	clustered	clustered	cluster	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O

Cardiac	NN	cardiac	cardiac	cardiac	N	O

Disorders	NNS	disorders	disorder	disord	N	O

Electrocardiogram	NNP	electrocardiogram	electrocardiogram	electrocardiogram	Y	B-AdverseReaction
QT	NNP	qt	qt	qt	N	I-AdverseReaction
prolonged	VBD	prolonged	prolonged	prolong	N	I-AdverseReaction
6	CD	6	6	6	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Eye	NN	eye	eye	eye	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Vision	NNP	vision	vision	vision	N	B-AdverseReaction
disorder	VBZ	disorder	disorder	disord	N	I-AdverseReaction
71	CD	71	71	71	N	O
1	CD	1	1	1	N	O
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
46	CD	46	46	46	N	O
2	CD	2	2	2	N	O
36	CD	36	36	36	N	O
3	CD	3	3	3	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
61	CD	61	61	61	N	O
2	CD	2	2	2	N	O
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
43	CD	43	43	43	N	O
2	CD	2	2	2	N	O
30	CD	30	30	30	N	O
0	CD	0	0	0	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
26	CD	26	26	26	N	O
0	CD	0	0	0	N	O
12	CD	12	12	12	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
49	CD	49	49	49	N	O
1	CD	1	1	1	N	O
12	CD	12	12	12	N	O
1	CD	1	1	1	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
32	CD	32	32	32	N	O
0	CD	0	0	0	N	O
12	CD	12	12	12	N	O
1	CD	1	1	1	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
8	CD	8	8	8	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
16	CD	16	16	16	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasm	VBD	spasm	spasm	spasm	N	I-AdverseReaction
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorder	NNP	disorder	disorder	disord	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
18	CD	18	18	18	N	O
0	CD	0	0	0	N	O
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
26	CD	26	26	26	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
22	CD	22	22	22	N	O
1	CD	1	1	1	N	O
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O

Additional	JJ	additional	additional	addit	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
overall	JJ	overall	overall	overal	N	O
incidence	NN	incidence	incidence	incid	N	O
between	IN	between	between	between	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
60%	CD	60%	60%	60%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
included	VBD	included	included	includ	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
56%	CD	56%	56%	56%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
(	(	(	(	(	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
29%	CD	29%	29%	29%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
(	(	(	(	(	N	O
21%	CD	21%	21%	21%	N	O
;	:	;	;	;	N	O
which	WDT	which	which	which	N	O
included	VBD	included	included	includ	N	O
gait	NN	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
,	,	,	,	,	N	O
hypoaesthesia	NN	hypoaesthesia	hypoaesthesia	hypoaesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
neuralgia	RB	neuralgia	neuralgia	neuralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
peripheral	NN	peripheral	peripheral	peripher	N	I-AdverseReaction
,	,	,	,	,	N	O
paraesthesia	NN	paraesthesia	paraesthesia	paraesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
polyneuropathy	NN	polyneuropathy	polyneuropathy	polyneuropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
sensory	JJ	sensory	sensory	sensori	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
cyst	NN	cyst	cyst	cyst	Y	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
;	:	;	;	;	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
,	,	,	,	,	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Summary	NNP	summary	summary	summari	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
Emergent	JJ	emergent	emergent	emerg	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
4%	CD	4%	4%	4%	N	O
in	IN	in	in	in	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormality	NNP	abnormality	abnormality	abnorm	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
Chemotherapy	NNP	chemotherapy	chemotherapy	chemotherapi	Y	O

Any	DT	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Any	DT	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

Neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction

52	CD	52	52	52	N	O
11	CD	11	11	11	N	O
59	CD	59	59	59	N	O
16	CD	16	16	16	N	O

Lymphopenia	NNP	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
48	CD	48	48	48	N	O
7	CD	7	7	7	N	O
53	CD	53	53	53	N	O
13	CD	13	13	13	N	O

Chemistry	NN	chemistry	chemistry	chemistri	N	O

ALT	NNP	alt	alt	alt	N	B-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
79	CD	79	79	79	N	O
15	CD	15	15	15	N	O
33	CD	33	33	33	N	O
2	CD	2	2	2	N	O

AST	NNP	ast	ast	ast	N	B-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
66	CD	66	66	66	N	O
8	CD	8	8	8	N	O
28	CD	28	28	28	N	O
1	CD	1	1	1	N	O

Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
32	CD	32	32	32	N	O
10	CD	10	10	10	N	O
21	CD	21	21	21	N	O
6	CD	6	6	6	N	O

Previously	RB	previously	previously	previous	N	O
Treated	VBN	treated	treated	treat	N	O
ALK	NNP	alk	alk	alk	N	O
-	:	-	-	-	N	O
Positive	JJ	positive	positive	posit	N	O
Metastatic	NNP	metastatic	metastatic	metastat	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
-	:	-	-	-	N	O
Study	NN	study	study	studi	N	O
2	CD	2	2	2	N	O

The	DT	the	the	the	N	O

data	NNS	data	data	data	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
are	VBP	are	are	are	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
343	CD	343	343	343	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
ALK	NNP	alk	alk	alk	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
,	,	,	,	,	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
arm	NN	arm	arm	arm	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
172	CD	172	172	172	N	O
)	)	)	)	)	N	O
received	VBD	received	received	receiv	N	O
XALKORI	$	xalkori	xalkori	xalkori	N	O
250	CD	250	250	250	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
twice	JJ	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
until	IN	until	until	until	N	O
documented	JJ	documented	documented	document	N	O
disease	NN	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
,	,	,	,	,	N	O
intolerance	NN	intolerance	intolerance	intoler	N	O
to	TO	to	to	to	N	O
therapy	VB	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
investigator	NN	investigator	investigator	investig	N	O
determined	VBD	determined	determined	determin	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
was	VBD	was	wa	wa	N	O
no	RB	no	no	no	N	O
longer	JJR	longer	longer	longer	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
clinical	JJ	clinical	clinical	clinic	N	O
benefit	NN	benefit	benefit	benefit	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
171	CD	171	171	171	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
arm	NN	arm	arm	arm	N	O
received	VBD	received	received	receiv	N	O
pemetrexed	JJ	pemetrexed	pemetrexed	pemetrex	N	O
500	CD	500	500	500	N	O
mg	NN	mg	mg	mg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
99	CD	99	99	99	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
docetaxel	$	docetaxel	docetaxel	docetaxel	N	O
75	CD	75	75	75	N	O
mg	NN	mg	mg	mg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
72	CD	72	72	72	N	O
)	)	)	)	)	N	O
by	IN	by	by	by	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
infusion	NN	infusion	infusion	infus	Y	O
every	DT	every	every	everi	N	O
three	CD	three	three	three	N	O
weeks	NNS	weeks	week	week	N	O
until	IN	until	until	until	N	O
documented	JJ	documented	documented	document	N	O
disease	NN	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
,	,	,	,	,	N	O
intolerance	NN	intolerance	intolerance	intoler	N	O
to	TO	to	to	to	N	O
therapy	VB	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
investigator	NN	investigator	investigator	investig	N	O
determined	VBD	determined	determined	determin	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
was	VBD	was	wa	wa	N	O
no	RB	no	no	no	N	O
longer	JJR	longer	longer	longer	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
clinical	JJ	clinical	clinical	clinic	N	O
benefit	NN	benefit	benefit	benefit	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
arm	NN	arm	arm	arm	N	O
received	VBD	received	received	receiv	N	O
pemetrexed	JJ	pemetrexed	pemetrexed	pemetrex	N	O
unless	IN	unless	unless	unless	N	O
they	PRP	they	they	they	N	O
had	VBD	had	had	had	N	O
received	VBN	received	received	receiv	N	O
pemetrexed	VBN	pemetrexed	pemetrexed	pemetrex	N	O
as	IN	as	a	as	N	O
part	NN	part	part	part	N	O
of	IN	of	of	of	N	O
first	JJ	first	first	first	N	O
-	:	-	-	-	N	O
line	NN	line	line	line	N	O
or	CC	or	or	or	N	O
maintenance	NN	maintenance	maintenance	mainten	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
study	NN	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
7.1	CD	7.1	7.1	7.1	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
and	CC	and	and	and	N	O
2.8	CD	2.8	2.8	2.8	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
347	CD	347	347	347	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
study	VB	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
(	(	(	(	(	N	O
343	CD	343	343	343	N	O
received	VBN	received	received	receiv	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
study	NN	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
50	CD	50	50	50	N	O
years	NNS	years	year	year	N	O
;	:	;	;	;	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
older	JJR	older	older	older	N	O
than	IN	than	than	than	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
56%	CD	56%	56%	56%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
45%	CD	45%	45%	45%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
64	CD	64	64	64	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
37.2%	CD	37.2%	37.2%	37.2%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
and	CC	and	and	and	N	O
40	CD	40	40	40	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
23.4%	CD	23.4%	23.4%	23.4%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
were	VBD	were	were	were	N	O
pneumonia	VBN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4.1%	CD	4.1%	4.1%	4.1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
(	(	(	(	(	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
(	(	(	(	(	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
(	(	(	(	(	N	O
2.9%	CD	2.9%	2.9%	2.9%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
consisting	VBG	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
:	:	:	:	:	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
,	,	,	,	,	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
,	,	,	,	,	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
and	CC	and	and	and	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
required	VBN	required	required	requir	N	O
in	IN	in	in	in	N	O
16%	CD	16%	16%	16%	N	O
of	IN	of	of	of	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
were	VBD	were	were	were	N	O
alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
)	)	)	)	)	N	O
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
(	(	(	(	(	N	O
7.6%	CD	7.6%	7.6%	7.6%	N	O
)	)	)	)	)	N	O
including	VBG	including	including	includ	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
aspartate	NN	aspartate	aspartate	aspart	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
)	)	)	)	)	N	O
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
,	,	,	,	,	N	O
QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
(	(	(	(	(	N	O
2.9%	CD	2.9%	2.9%	2.9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

XALKORI	NN	xalkori	xalkori	xalkori	N	O
was	VBD	was	wa	wa	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
for	IN	for	for	for	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
were	VBD	were	were	were	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
(	(	(	(	(	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
and	CC	and	and	and	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
(	(	(	(	(	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
(	(	(	(	(	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Tables	NNS	tables	table	tabl	N	O
5	CD	5	5	5	N	O
and	CC	and	and	and	N	O
6	CD	6	6	6	N	O
summarize	JJ	summarize	summarize	summar	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
in	IN	in	in	in	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NNP	incidence	incidence	incid	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
Higher	JJR	higher	higher	higher	N	O
for	IN	for	for	for	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
or	CC	or	or	or	N	O
2%	CD	2%	2%	2%	N	O
Higher	JJR	higher	higher	higher	N	O
for	IN	for	for	for	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
than	IN	than	than	than	N	O
Chemotherapy	NNP	chemotherapy	chemotherapy	chemotherapi	Y	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
172	CD	172	172	172	N	O
)	)	)	)	)	N	O
Chemotherapy	NNP	chemotherapy	chemotherapy	chemotherapi	Y	O
(	(	(	(	(	N	O
Pemetrexed	NNP	pemetrexed	pemetrexed	pemetrex	N	O
or	CC	or	or	or	N	O
Docetaxel	NNP	docetaxel	docetaxel	docetaxel	N	O
)(	NNP	)(	)(	)(	N	O
N	NNP	n	n	n	N	O
171	CD	171	171	171	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Includes	NNS	includes	includes	includ	N	O

cases	NNS	cases	case	case	N	O
reported	VBD	reported	reported	report	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
clustered	JJ	clustered	clustered	cluster	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O

System	NN	system	system	system	N	O
Disorder	NNP	disorder	disorder	disord	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
22	CD	22	22	22	N	O
1	CD	1	1	1	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
26	CD	26	26	26	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O

Syncope	NNP	syncope	syncope	syncop	Y	B-AdverseReaction
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Eye	NN	eye	eye	eye	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Vision	NNP	vision	vision	vision	N	B-AdverseReaction
disorder	VBZ	disorder	disorder	disord	N	I-AdverseReaction
60	CD	60	60	60	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Electrocardiogram	NNP	electrocardiogram	electrocardiogram	electrocardiogram	Y	B-AdverseReaction
QT	NNP	qt	qt	qt	N	I-AdverseReaction
prolonged	VBD	prolonged	prolonged	prolong	N	I-AdverseReaction
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
47	CD	47	47	47	N	O
1	CD	1	1	1	N	O
18	CD	18	18	18	N	O
0	CD	0	0	0	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
55	CD	55	55	55	N	O
1	CD	1	1	1	N	O
37	CD	37	37	37	N	O
1	CD	1	1	1	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
60	CD	60	60	60	N	O
0	CD	0	0	0	N	O
19	CD	19	19	19	N	O
1	CD	1	1	1	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
42	CD	42	42	42	N	O
2	CD	2	2	2	N	O
23	CD	23	23	23	N	O
0	CD	0	0	0	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
26	CD	26	26	26	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
6	CD	6	6	6	N	O
5	CD	5	5	5	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
31	CD	31	31	31	N	O
0	CD	0	0	0	N	O
16	CD	16	16	16	N	O
0	CD	0	0	0	N	O

Additional	JJ	additional	additional	addit	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
overall	JJ	overall	overall	overal	N	O
incidence	NN	incidence	incidence	incid	N	O
between	IN	between	between	between	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
30%	CD	30%	30%	30%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
included	VBD	included	included	includ	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
27%	CD	27%	27%	27%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
(	(	(	(	(	N	O
19%	CD	19%	19%	19%	N	O
;	:	;	;	;	N	O
dysesthesia	NN	dysesthesia	dysesthesia	dysesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
gait	NN	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
,	,	,	,	,	N	O
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
neuralgia	RB	neuralgia	neuralgia	neuralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
parasthesia	NN	parasthesia	parasthesia	parasthesia	N	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
polyneuropathy	NN	polyneuropathy	polyneuropathy	polyneuropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
burning	VBG	burning	burning	burn	N	B-AdverseReaction
sensation	NN	sensation	sensation	sensat	N	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
;	:	;	;	;	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
,	,	,	,	,	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
cyst	NN	cyst	cyst	cyst	Y	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

6	CD	6	6	6	N	O
.	.	.	.	.	N	O

Summary	NNP	summary	summary	summari	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
Emergent	JJ	emergent	emergent	emerg	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
4%	CD	4%	4%	4%	N	O
in	IN	in	in	in	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O

Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormality	NNP	abnormality	abnormality	abnorm	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
Chemotherapy	NNP	chemotherapy	chemotherapy	chemotherapi	Y	O

Any	DT	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Any	DT	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

Neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction

49	CD	49	49	49	N	O
12	CD	12	12	12	N	O
28	CD	28	28	28	N	O
12	CD	12	12	12	N	O

Lymphopenia	NNP	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
51	CD	51	51	51	N	O
9	CD	9	9	9	N	O
60	CD	60	60	60	N	O
25	CD	25	25	25	N	O

Chemistry	NN	chemistry	chemistry	chemistri	N	O

ALT	NNP	alt	alt	alt	N	B-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
76	CD	76	76	76	N	O
17	CD	17	17	17	N	O
38	CD	38	38	38	N	O
4	CD	4	4	4	N	O

AST	NNP	ast	ast	ast	N	B-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
61	CD	61	61	61	N	O
9	CD	9	9	9	N	O
33	CD	33	33	33	N	O
0	CD	0	0	0	N	O

Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
18	CD	18	18	18	N	O
4	CD	4	4	4	N	O
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O

Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
28	CD	28	28	28	N	O
5	CD	5	5	5	N	O
25	CD	25	25	25	N	O
6	CD	6	6	6	N	O

Description	NN	description	description	descript	N	O
of	IN	of	of	of	N	O
Selected	NNP	selected	selected	select	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Drug	NNP	drug	drug	drug	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Vision	NN	vision	vision	vision	N	O

disorders	NNS	disorders	disorder	disord	N	O

Vision	NN	vision	vision	vision	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
most	JJS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
photopsia	NN	photopsia	photopsia	photopsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
vitreous	JJ	vitreous	vitreous	vitreou	N	B-AdverseReaction
floaters	NNS	floaters	floater	floater	Y	I-AdverseReaction
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1038	CD	1038	1038	1038	N	O
(	(	(	(	(	N	O
62%	CD	62%	62%	62%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
1669	CD	1669	1669	1669	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
Grade	VBN	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
visual	JJ	visual	visual	visual	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
and	CC	and	and	and	N	O
4	CD	4	4	4	N	I-Severity
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
visual	JJ	visual	visual	visual	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
Visual	NNP	visual	visual	visual	N	O
Symptom	NNP	symptom	symptom	symptom	N	O
Assessment	NNP	assessment	assessment	assess	N	O
Questionnaire	NNP	questionnaire	questionnaire	questionnair	N	O
(	(	(	(	(	N	O
VSAQ	NNP	vsaq	vsaq	vsaq	N	O
-	:	-	-	-	N	O
ALK	NNP	alk	alk	alk	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
reported	VBD	reported	reported	report	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
disturbances	NNS	disturbances	disturbance	disturb	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
generally	RB	generally	generally	gener	N	O
was	VBD	was	wa	wa	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
week	NN	week	week	week	N	O
of	IN	of	of	of	N	O
drug	NN	drug	drug	drug	N	O
administration	NN	administration	administration	administr	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
XALKORI	NN	xalkori	xalkori	xalkori	N	O
arms	NNS	arms	arm	arm	N	O
in	IN	in	in	in	N	O
Studies	NNS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
50%	CD	50%	50%	50%	N	O
)	)	)	)	)	N	O
reported	VBD	reported	reported	report	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
disturbances	NNS	disturbances	disturbance	disturb	N	I-AdverseReaction
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
each	DT	each	each	each	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
lasted	VBD	lasted	lasted	last	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
1	CD	1	1	1	N	O
minute	NN	minute	minute	minut	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
mild	VBN	mild	mild	mild	N	O
or	CC	or	or	or	N	O
no	DT	no	no	no	N	O
impact	NN	impact	impact	impact	N	O
(	(	(	(	(	N	O
scores	VBZ	scores	score	score	N	O
0	CD	0	0	0	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
maximum	JJ	maximum	maximum	maximum	N	O
score	NN	score	score	score	N	O
of	IN	of	of	of	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
on	IN	on	on	on	N	O
daily	JJ	daily	daily	daili	N	O
activities	NNS	activities	activity	activ	N	O
as	IN	as	a	as	N	O
captured	VBN	captured	captured	captur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
VSAQ	NNP	vsaq	vsaq	vsaq	N	O
-	:	-	-	-	N	O
ALK	NNP	alk	alk	alk	N	O
questionnaire	NN	questionnaire	questionnaire	questionnair	N	O
.	.	.	.	.	N	O

Neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O

Neuropathy	NNP	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
most	JJS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
sensory	JJ	sensory	sensory	sensori	N	I-AdverseReaction
in	IN	in	in	in	N	O
nature	NN	nature	nature	natur	N	O
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
419	CD	419	419	419	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
1669	CD	1669	1669	1669	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
Grade	VBN	grade	grade	grade	N	O
1	CD	1	1	1	N	O
or	CC	or	or	or	N	O
Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
in	IN	in	in	in	N	O
severity	NN	severity	severity	sever	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	O
Cysts	NNS	cysts	cyst	cyst	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
cysts	NNS	cysts	cyst	cyst	N	I-AdverseReaction
were	VBD	were	were	were	N	O
experienced	VBN	experienced	experienced	experienc	N	O
by	IN	by	by	by	N	O
50	CD	50	50	50	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
1669	CD	1669	1669	1669	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
cysts	NNS	cysts	cyst	cyst	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
cysts	NNS	cysts	cyst	cyst	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
cysts	NNS	cysts	cyst	cyst	N	I-AdverseReaction
in	IN	in	in	in	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
complex	JJ	complex	complex	complex	N	I-AdverseReaction
.	.	.	.	.	N	O

Local	JJ	local	local	local	N	B-AdverseReaction
cystic	JJ	cystic	cystic	cystic	N	I-AdverseReaction
invasion	NN	invasion	invasion	invas	N	I-AdverseReaction
beyond	IN	beyond	beyond	beyond	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
kidney	NN	kidney	kidney	kidney	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
with	IN	with	with	with	N	O
imaging	VBG	imaging	imaging	imag	N	O
characteristics	NNS	characteristics	characteristic	characterist	N	O
suggestive	JJ	suggestive	suggestive	suggest	N	B-Factor
of	IN	of	of	of	N	O
abscess	JJ	abscess	abscess	abscess	Y	B-AdverseReaction
formation	NN	formation	formation	format	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
no	DT	no	no	no	N	B-Negation
renal	JJ	renal	renal	renal	N	B-AdverseReaction
abscesses	NNS	abscesses	abscess	abscess	N	I-AdverseReaction
were	VBD	were	were	were	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
by	IN	by	by	by	N	O
microbiology	NN	microbiology	microbiology	microbiolog	N	O
tests	NNS	tests	test	test	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
:	:	:	:	:	N	O
Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
with	IN	with	with	with	N	O
periodic	JJ	periodic	periodic	period	N	O
liver	NN	liver	liver	liver	N	O
testing	NN	testing	testing	test	N	O
.	.	.	.	.	N	O

Temporarily	RB	temporarily	temporarily	temporarili	N	O
suspend	VB	suspend	suspend	suspend	N	O
,	,	,	,	,	N	O
dose	VB	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
Lung	NNP	lung	lung	lung	N	I-AdverseReaction
Disease	NNP	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
)	)	)	)	)	N	O
Pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
:	:	:	:	:	N	O
Occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2.9%	CD	2.9%	2.9%	2.9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
ILD	NNP	ild	ild	ild	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

QT	NNP	qt	qt	qt	N	B-AdverseReaction
Interval	NNP	interval	interval	interv	N	I-AdverseReaction
Prolongation	NNP	prolongation	prolongation	prolong	N	I-AdverseReaction
:	:	:	:	:	N	O
Occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2.1%	CD	2.1%	2.1%	2.1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
with	IN	with	with	with	N	O
electrocardiograms	NNS	electrocardiograms	electrocardiogram	electrocardiogram	N	O
and	CC	and	and	and	N	O
electrolytes	NNS	electrolytes	electrolyte	electrolyt	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
or	CC	or	or	or	N	O
predisposition	NN	predisposition	predisposition	predisposit	N	O
for	IN	for	for	for	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
prolongation	NN	prolongation	prolongation	prolong	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
taking	VBG	taking	taking	take	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
prolong	VBP	prolong	prolong	prolong	N	O
QT	NNP	qt	qt	qt	N	O
.	.	.	.	.	N	O

Temporarily	RB	temporarily	temporarily	temporarili	N	O
suspend	VB	suspend	suspend	suspend	N	O
,	,	,	,	,	N	O
dose	VB	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
:	:	:	:	:	N	O
XALKORI	NN	xalkori	xalkori	xalkori	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
and	CC	and	and	and	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
regularly	RB	regularly	regularly	regularli	N	O
.	.	.	.	.	N	O

Temporarily	RB	temporarily	temporarily	temporarili	N	O
suspend	VB	suspend	suspend	suspend	N	O
,	,	,	,	,	N	O
dose	VB	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Severe	JJ	severe	severe	sever	N	B-Severity
Visual	JJ	visual	visual	visual	N	B-AdverseReaction
Loss	NN	loss	loss	loss	N	I-AdverseReaction
:	:	:	:	:	N	O
Reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
visual	JJ	visual	visual	visual	N	O
loss	NN	loss	loss	loss	N	O
.	.	.	.	.	N	O

Perform	VB	perform	perform	perform	N	O
an	DT	an	an	an	N	O
ophthalmological	JJ	ophthalmological	ophthalmological	ophthalmolog	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
and	CC	and	and	and	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
,	,	,	,	,	N	O
8.1	CD	8.1	8.1	8.1	N	O
,	,	,	,	,	N	O
8.3	CD	8.3	8.3	8.3	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O

Drug	NN	drug	drug	drug	N	O

-	:	-	-	-	N	O
induced	VBN	induced	induced	induc	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
with	IN	with	with	with	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
1669	CD	1669	1669	1669	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
.	.	.	.	.	N	O

Concurrent	JJ	concurrent	concurrent	concurr	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
alanine	JJ	alanine	alanine	alanin	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
aspartate	JJ	aspartate	aspartate	aspart	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
)	)	)	)	)	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
three	CD	three	three	three	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
(	(	(	(	(	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
)	)	)	)	)	N	I-Severity
and	CC	and	and	and	N	O
total	JJ	total	total	total	N	B-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
two	CD	two	two	two	N	I-AdverseReaction
times	NNS	times	time	time	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
alkaline	JJ	alkaline	alkaline	alkalin	N	O
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	O
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
10	CD	10	10	10	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
five	CD	five	five	five	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
184	CD	184	184	184	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
93	CD	93	93	93	N	O
(	(	(	(	(	N	O
5.7%	CD	5.7%	5.7%	5.7%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Seventeen	JJ	seventeen	seventeen	seventeen	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
)	)	)	)	)	N	O
required	VBN	required	required	requir	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
.	.	.	.	.	N	O

Transaminase	NN	transaminase	transaminase	transaminas	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
generally	RB	generally	generally	gener	N	O
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
with	IN	with	with	with	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
including	VBG	including	including	includ	N	O
ALT	NNP	alt	alt	alt	N	O
and	CC	and	and	and	N	O
total	JJ	total	total	total	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
every	DT	every	every	everi	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
once	RB	once	once	onc	N	O
a	DT	a	a	a	N	O
month	NN	month	month	month	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
repeat	NN	repeat	repeat	repeat	N	O
testing	VBG	testing	testing	test	N	O
for	IN	for	for	for	N	O
increased	VBN	increased	increased	increas	N	O
liver	NN	liver	liver	liver	N	O
transaminases	NNS	transaminases	transaminase	transaminas	Y	O
,	,	,	,	,	N	O
alkaline	JJ	alkaline	alkaline	alkalin	N	O
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
total	JJ	total	total	total	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
transaminase	JJ	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
.	.	.	.	.	N	O

Temporarily	RB	temporarily	temporarily	temporarili	N	O
suspend	VB	suspend	suspend	suspend	N	O
,	,	,	,	,	N	O
dose	VB	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
as	IN	as	a	as	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
[	NN	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Interstitial	JJ	interstitial	interstitial	interstiti	N	O
Lung	NNP	lung	lung	lung	N	O
Disease	NNP	disease	disease	diseas	N	O
(	(	(	(	(	N	O
Pneumonitis	NNP	pneumonitis	pneumonitis	pneumon	Y	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
)	)	)	)	)	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1669	CD	1669	1669	1669	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
49	CD	49	49	49	N	O
XALKORI	SYM	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2.9%	CD	2.9%	2.9%	2.9%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
,	,	,	,	,	N	O
18	CD	18	18	18	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
Grade	VBN	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
8	CD	8	8	8	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
generally	RB	generally	generally	gener	N	O
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
indicative	JJ	indicative	indicative	indic	N	O
of	IN	of	of	of	N	O
ILD	NNP	ild	ild	ild	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
.	.	.	.	.	N	O

Exclude	NNP	exclude	exclude	exclud	N	O
other	JJ	other	other	other	N	O
potential	JJ	potential	potential	potenti	N	O
causes	NNS	causes	cause	caus	N	O
of	IN	of	of	of	N	O
ILD	NNP	ild	ild	ild	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
with	IN	with	with	with	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
ILD	NNP	ild	ild	ild	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
QT	NNP	qt	qt	qt	N	O
Interval	NNP	interval	interval	interv	N	O
Prolongation	NNP	prolongation	prolongation	prolong	N	O

QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
32	CD	32	32	32	N	O
of	IN	of	of	of	N	O
1560	CD	1560	1560	1560	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2.1%	CD	2.1%	2.1%	2.1%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
QTcF	NNP	qtcf	qtcf	qtcf	N	B-AdverseReaction
(	(	(	(	(	N	O
corrected	VBN	corrected	corrected	correct	N	O
QT	NNP	qt	qt	qt	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
Fridericia	NNP	fridericia	fridericia	fridericia	N	O
method	NN	method	method	method	N	O
)	)	)	)	)	N	O
greater	JJR	greater	greater	greater	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
or	CC	or	or	or	N	I-AdverseReaction
equal	JJ	equal	equal	equal	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
500	CD	500	500	500	N	I-AdverseReaction
ms	NNS	ms	m	ms	Y	I-AdverseReaction
and	CC	and	and	and	N	O
76	CD	76	76	76	N	O
of	IN	of	of	of	N	O
1520	CD	1520	1520	1520	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
5.0%	CD	5.0%	5.0%	5.0%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	JJ	baseline	baseline	baselin	N	O
QTcF	NNP	qtcf	qtcf	qtcf	N	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
60	CD	60	60	60	N	B-Severity
ms	NNS	ms	m	ms	Y	I-Severity
by	IN	by	by	by	N	O
automated	JJ	automated	automated	autom	N	O
machine	NN	machine	machine	machin	N	O
-	:	-	-	-	N	O
read	JJ	read	read	read	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
ECG	NNP	ecg	ecg	ecg	Y	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
XALKORI	NN	xalkori	xalkori	xalkori	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
congenital	JJ	congenital	congenital	congenit	N	O
long	JJ	long	long	long	N	O
QT	NNP	qt	qt	qt	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
periodic	JJ	periodic	periodic	period	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
with	IN	with	with	with	N	O
electrocardiograms	NNS	electrocardiograms	electrocardiogram	electrocardiogram	N	O
(	(	(	(	(	N	O
ECGs	NNP	ecgs	ecg	ecg	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
electrolytes	VBZ	electrolytes	electrolyte	electrolyt	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
congestive	JJ	congestive	congestive	congest	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
bradyarrhythmias	NN	bradyarrhythmias	bradyarrhythmias	bradyarrhythmia	N	O
,	,	,	,	,	N	O
electrolyte	JJ	electrolyte	electrolyte	electrolyt	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
taking	VBG	taking	taking	take	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
prolong	VB	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
500	CD	500	500	500	N	O
ms	NN	ms	m	ms	Y	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
60	CD	60	60	60	N	O
ms	NNS	ms	m	ms	Y	O
change	VBP	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
with	IN	with	with	with	N	O
Torsade	NNP	torsade	torsade	torsad	N	O
de	FW	de	de	de	N	O
pointes	VBZ	pointes	pointes	point	N	O
or	CC	or	or	or	N	O
polymorphic	JJ	polymorphic	polymorphic	polymorph	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	O
or	CC	or	or	or	N	O
signs	NNS	signs	sign	sign	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
500	CD	500	500	500	N	O
ms	NN	ms	m	ms	Y	O
on	IN	on	on	on	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
separate	JJ	separate	separate	separ	N	O
ECGs	NNP	ecgs	ecg	ecg	N	O
until	IN	until	until	until	N	O
recovery	NN	recovery	recovery	recoveri	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
480	CD	480	480	480	N	O
ms	NNS	ms	m	ms	Y	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
resume	VB	resume	resume	resum	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
as	IN	as	a	as	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
[	NN	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	O

Symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	I-AdverseReaction
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
205	CD	205	205	205	N	O
(	(	(	(	(	N	O
12.3%	CD	12.3%	12.3%	12.3%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
1669	CD	1669	1669	1669	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
242	CD	242	242	242	N	O
(	(	(	(	(	N	O
14.9%	CD	14.9%	14.9%	14.9%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
50	CD	50	50	50	N	I-AdverseReaction
beats	NNS	beats	beat	beat	N	I-AdverseReaction
per	IN	per	per	per	N	I-AdverseReaction
minute	NN	minute	minute	minut	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
Grade	VBD	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
of	IN	of	of	of	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
using	VBG	using	using	use	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
agents	NNS	agents	agent	agent	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
beta	SYM	beta	beta	beta	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
dihydropyridine	NN	dihydropyridine	dihydropyridine	dihydropyridin	N	O
calcium	NN	calcium	calcium	calcium	Y	O
channel	NN	channel	channel	channel	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
clonidine	NN	clonidine	clonidine	clonidin	N	O
and	CC	and	and	and	N	O
digoxin	NN	digoxin	digoxin	digoxin	N	O
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
extent	NN	extent	extent	extent	N	O
possible	JJ	possible	possible	possibl	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
and	CC	and	and	and	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
regularly	RB	regularly	regularly	regularli	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	NN	threatening	threatening	threaten	N	O
,	,	,	,	,	N	O
hold	VBP	hold	hold	hold	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
until	IN	until	until	until	N	O
recovery	NN	recovery	recovery	recoveri	N	O
to	TO	to	to	to	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
60	CD	60	60	60	N	O
bpm	NN	bpm	bpm	bpm	N	O
or	CC	or	or	or	N	O
above	IN	above	above	abov	N	O
,	,	,	,	,	N	O
re	VB	re	re	re	N	O
-	:	-	-	-	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
adjust	VBP	adjust	adjust	adjust	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
for	IN	for	for	for	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	JJ	threatening	threatening	threaten	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
or	CC	or	or	or	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
,	,	,	,	,	N	O
hold	VBP	hold	hold	hold	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
until	IN	until	until	until	N	O
recovery	NN	recovery	recovery	recoveri	N	O
to	TO	to	to	to	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
60	CD	60	60	60	N	O
bpm	NN	bpm	bpm	bpm	N	O
or	CC	or	or	or	N	O
above	NN	above	above	abov	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
if	IN	if	if	if	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
adjusted	VBN	adjusted	adjusted	adjust	N	O
or	CC	or	or	or	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
,	,	,	,	,	N	O
restart	VB	restart	restart	restart	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
at	IN	at	at	at	N	O
250	CD	250	250	250	N	O
mg	NNS	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
with	IN	with	with	with	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Severe	JJ	severe	severe	sever	N	O
Visual	NNP	visual	visual	visual	N	O
Loss	NNP	loss	loss	loss	N	O

Across	IN	across	across	across	N	O
all	DT	all	all	all	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
visual	JJ	visual	visual	visual	N	B-AdverseReaction
field	NN	field	field	field	N	I-AdverseReaction
defect	NN	defect	defect	defect	N	I-AdverseReaction
with	IN	with	with	with	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
1669	CD	1669	1669	1669	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Optic	JJ	optic	optic	optic	N	B-AdverseReaction
atrophy	NN	atrophy	atrophy	atrophi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
optic	JJ	optic	optic	optic	N	B-AdverseReaction
nerve	NN	nerve	nerve	nerv	N	I-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
potential	JJ	potential	potential	potenti	N	B-Factor
causes	NNS	causes	cause	caus	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
new	JJ	new	new	new	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
visual	JJ	visual	visual	visual	N	O
loss	NN	loss	loss	loss	N	O
(	(	(	(	(	N	O
best	JJS	best	best	best	N	O
corrected	VBN	corrected	corrected	correct	N	O
vision	NN	vision	vision	vision	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
20	CD	20	20	20	N	O
200	CD	200	200	200	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
both	DT	both	both	both	N	O
eyes	NNS	eyes	eye	eye	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Perform	VB	perform	perform	perform	N	O
an	DT	an	an	an	N	O
ophthalmological	JJ	ophthalmological	ophthalmological	ophthalmolog	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
consisting	NN	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
best	RB	best	best	best	N	O
corrected	VBN	corrected	corrected	correct	N	O
visual	JJ	visual	visual	visual	N	O
acuity	NN	acuity	acuity	acuiti	N	O
,	,	,	,	,	N	O
retinal	JJ	retinal	retinal	retin	N	O
photographs	NN	photographs	photograph	photograph	N	O
,	,	,	,	,	N	O
visual	JJ	visual	visual	visual	N	O
fields	NNS	fields	field	field	N	O
,	,	,	,	,	N	O
optical	JJ	optical	optical	optic	N	O
coherence	NN	coherence	coherence	coher	N	O
tomography	NN	tomography	tomography	tomographi	N	O
(	(	(	(	(	N	O
OCT	NNP	oct	oct	oct	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
evaluations	NNS	evaluations	evaluation	evalu	N	O
as	IN	as	a	as	N	O
appropriate	NN	appropriate	appropriate	appropri	N	O
for	IN	for	for	for	N	O
new	JJ	new	new	new	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
visual	JJ	visual	visual	visual	N	O
loss	NN	loss	loss	loss	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
information	NN	information	information	inform	N	O
to	TO	to	to	to	N	O
characterize	VB	characterize	characterize	character	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
resumption	NN	resumption	resumption	resumpt	N	O
of	IN	of	of	of	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
severe	JJ	severe	severe	sever	N	O
visual	JJ	visual	visual	visual	N	O
loss	NN	loss	loss	loss	N	O
;	:	;	;	;	N	O
a	DT	a	a	a	N	O
decision	NN	decision	decision	decis	N	O
to	TO	to	to	to	N	O
resume	VB	resume	resume	resum	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
should	MD	should	should	should	N	O
consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
benefits	NNS	benefits	benefit	benefit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
its	PRP$	its	it	it	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
,	,	,	,	,	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
animal	JJ	animal	animal	anim	N	O
reproduction	NN	reproduction	reproduction	reproduct	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
crizotinib	NN	crizotinib	crizotinib	crizotinib	N	O
in	IN	in	in	in	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
rats	NNS	rats	rat	rat	N	B-Animal
during	IN	during	during	dure	N	O
organogenesis	NN	organogenesis	organogenesis	organogenesi	N	O
at	IN	at	at	at	N	O
exposures	NNS	exposures	exposure	exposur	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
maximum	NN	maximum	maximum	maximum	N	O
recommended	VBD	recommended	recommended	recommend	N	O
human	JJ	human	human	human	N	O
dose	NN	dose	dose	dose	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
embryotoxicity	NN	embryotoxicity	embryotoxicity	embryotox	N	B-AdverseReaction
and	CC	and	and	and	N	O
fetotoxicity	NN	fetotoxicity	fetotoxicity	fetotox	N	B-AdverseReaction
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
use	VB	use	use	use	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
XALKORI	NNP	xalkori	xalkori	xalkori	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
45	CD	45	45	45	N	O
days	NNS	days	day	day	N	O
following	VBG	following	following	follow	N	O
the	DT	the	the	the	N	O
final	JJ	final	final	final	N	O
dose	NN	dose	dose	dose	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
,	,	,	,	,	N	O
8.3	CD	8.3	8.3	8.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

